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Background
TMS studies on the CNS effects of benzodiazepines have
provided contradictory results. The objective of the study
is to describe the effects of lorazepam on silent period
(SP), corticomotor threshold and activated MEP recruit-
ment curves.
Materials and methods
Twelve healthy male subjects (median age 35 years) were
studied at baseline, following i.v. lorazepam administra-
tion and after reversal of the benzodiazepine effects with
i.v. flumazenil. Lorazepam was given at a low-dose in one
subject (0.0225 mg/kg bolus + 2 μg/kg/h infusion) and at
a high-dose (0.045 mg/kg bolus + 2.6 μg/kg/h infusion)
in the rest. Threshold (Thr) was measured at 1% steps. SPs
were investigated with two complementary methods.
First, SPs were elicited using a wide range of stimulus
intensities (SIs) (from 5 to 100% maximum SI at 5%
increments). At each SI, 4 SPs were obtained and the aver-
age value of SP duration was used to construct a stimulus/
response (S/R) curve of SI vs. SP. The resulting S/R curves
were then fitted to a Boltzman function, the best-fit values
of which were statistically compared for each experimen-
tal condition (i.e., baseline vs. lorazepam vs. flumazenil).
Second, a large number of SPs was elicited during the
three experimental conditions using blocks of 4 stimuli
with an intensity alternating between MT and 200% MT.
This method was employed so as to reveal the dynamic,
time-varying effects of lorazepam and flumazenil on SP
duration at two stimulus intensity (SI) levels. Finally,
active MEP recruitment curves were constructed and fitted
to a Boltzman function the best-fit values of which were
statistically compared for each experimental condition.
Results
Lorazepam at a low dose did not affect Thr, SP or the MEP
recruitment curves. The high dose had also no effect on
Thr (38.4 ± 7.3% vs. 39.8 ± 8.8% vs. 39.6 ± 8.9%, p >
0.05). In contrast, the Max value of the SP S/R curve
decreased from 250.8 ± 30.3 ms at baseline to 206.8 ±
14.6 ms post-lorazepam (p < 0.01). V50 also decreased
significantly (from 48.6 ± 3.7% to 43.1 ± 5.5%, p < 0.01)
whereas there was no significant change regarding slope.
The statistical analysis of the SP S/R curves as well as the
study of SPs at two SI levels revealed that lorazepam
reduced SP duration when high intensity stimuli were
used (>60%). These effects of lorazepam on SP were par-
tially reversed by flumazenil. At low SIs a small increase in
SP duration was noted. Active MEP recruitment curves
were not depressed by lorazepam administration.
Discussion
Enhancement of GABAergic inhibition by lorazepam
results in: reduction of SP duration when high SIs are used
and an increase, to a smaller degree, at the lower range of
SIs. The kinetic behavior of this phenomenon as well as
the possible underlying mechanisms are discussed.
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